NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) — DemeRx IB, Inc. (“DemeRx”), an atai Life Sciences (Nasdaq: ATAI) (“atai”) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced that the first subjects have been dosed in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002). The trial has commenced enrollment and dosing of recreational drug…


Previous articleMindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its 5-MeO-DMT-Inspired Drug Candidate, MSP-4018
Next articleAre Prodrugs the Next Wave of Psychedelic Drug Development?